Journal of Clinical Oncology
Articles in this Issue
Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial
Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
Upfront Modified FOLFOXIRI Plus Panitumumab for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study
We report 5-year results of the phase III randomized TRIPLETE study. Eligible patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) received firs...
Assessing the Benefit of Specialist Palliative Care in Oncology: Rethinking Clinical Trial Design
Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?
Reply to: “NeoADAURA: Can We Afford to Overlook Objective Response Rates?” and “Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?”
Music Therapy Versus Cognitive Behavioral Therapy via Telehealth for Anxiety in Survivors of Cancer: A Randomized Clinical Trial
PURPOSE Anxiety is prevalent, disruptive, and undertreated among survivors of cancer. Cognitive behavioral therapy (CBT) is the first-line treatment, but not all individuals have a...
Sustained Benefit of Blinatumomab in Infants With <i>KMT2A</i> -Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics
KMT2A -rearranged infant ALL ( KMT2A -r ALL) has a poor prognosis. Adding blinatumomab, a bispecific T-cell engager targeting CD19, to stand...
Mother's Grief
A pediatric oncologist's experience of a patient's death through the new lens of motherhood
Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study
PURPOSE Circulating tumor DNA (ctDNA) is emerging as a promising tool to monitor treatment response in large B-cell lymphoma (LBCL). Tracking tumor-specific phased variants (PVs) a...
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma
PURPOSE End-of-treatment (EOT) response evaluation by positron emission tomography (PET) remains suboptimal in patients with large B-cell lymphoma (LBCL), because of its limited po...
Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma
PURPOSE Extranodal extension (ENE) is a biomarker in oropharyngeal carcinoma (OPC) but can only be diagnosed via surgical pathology. We applied an automated artificial intelligence...